Clinical Review

Adjuvant Systemic Therapy for Early-Stage Breast Cancer


 

Over the past 20 years, substantial progress has been achieved in our understanding of breast cancer and in breast cancer treatment, with mortality from breast cancer declining by more than 25% over this time. This progress has been characterized by a greater understanding of the molecular biology of breast cancer, rational drug design, development of agents with specific cellular targets and pathways, development of better prognostic and predictive multigene assays, and marked improvements in supportive care.

To read the full article in PDF:

Click here

Recommended Reading

Menopause status could guide breast cancer screening interval
Breast Cancer ICYMI
American Cancer Society recommends annual mammography starting at age 45
Breast Cancer ICYMI
Study finds no link between thyroid autoimmunity, breast cancer outcomes
Breast Cancer ICYMI
Will New American Cancer Society Mammography Policy Change VHA Practice?
Breast Cancer ICYMI
DenseBreast-info.org: What this resource can offer you, and your patients
Breast Cancer ICYMI
Managing menopausal symptoms after risk-reducing salpingo-oophorectomy
Breast Cancer ICYMI
What you should know about the latest change in mammography screening guidelines
Breast Cancer ICYMI
Gene mutations had little impact on everolimus benefit in advanced breast cancer
Breast Cancer ICYMI
How to individualize cancer risk reduction after a diagnosis of DCIS
Breast Cancer ICYMI
Partial breast irradiation valid option to prevent local recurrence
Breast Cancer ICYMI